Pluristem Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, PSTI, Pluristem Therapeutics Inc, priceseries

Pluristem Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
2.01
Close
1.82
High
2.04
Low
1.81
Previous Close
2.05
Daily Price Gain
-0.23
YTD High
2.27
YTD High Date
Jan 18, 2022
YTD Low
1.36
YTD Low Date
Jan 6, 2022
YTD Price Change
0.31
YTD Gain
20.53%
52 Week High
5.89
52 Week High Date
Mar 18, 2021
52 Week Low
1.36
52 Week Low Date
Jan 6, 2022
52 Week Price Change
-3.05
52 Week Gain
-62.63%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 31. 2017
12.30
Apr 18. 2017
13.98
11 Trading Days
13.66%
Link
LONG
Oct 9. 2017
15.60
Oct 30. 2017
17.50
15 Trading Days
12.18%
Link
LONG
Jan 2. 2019
8.87
Feb 4. 2019
11.31
22 Trading Days
27.46%
Link
LONG
Apr 29. 2019
6.09
May 13. 2019
6.41
10 Trading Days
5.10%
Link
LONG
Sep 3. 2019
3.74
Sep 20. 2019
4.19
13 Trading Days
12.03%
Link
LONG
Feb 13. 2020
3.89
Feb 24. 2020
4.25
6 Trading Days
9.18%
Link
LONG
Apr 8. 2020
4.85
Apr 29. 2020
8.92
14 Trading Days
83.88%
Link
LONG
Jun 22. 2020
7.74
Jul 10. 2020
8.72
13 Trading Days
12.71%
Link
LONG
Jul 29. 2020
9.00
Aug 6. 2020
9.51
6 Trading Days
5.67%
Link
LONG
Apr 28. 2021
4.52
Apr 29. 2021
4.79
1 Trading Days
5.97%
Link
LONG
Jan 12. 2022
1.74
Jan 20. 2022
1.84
5 Trading Days
5.75%
Link
Company Information
Stock Symbol
PSTI
Exchange
NasdaqCM
Company URL
http://www.pluristem.com
Company Phone
972-74-710-7171
CEO
Zami Aberman
Headquarters
-
Business Address
MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, ISRAEL 31905
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001158780
About

Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development. It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others. Its products include PLacental eXpanded, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Description

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading